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Mice infected with mouse hepatitis virus A59 (MHV-A59), an enveloped, positive-strand RNA Co-
ronavirus, induce hepatitis, thymus involution, IgG2a-restricted hypergammaglobulinaemia, 
transaminase release and autoantibodies (autoAb) to liver and kidney fumarylacetoacetate hy-
drolase (FAH). Since Toll-like receptors (TLR) play a central role in innate immunity, we explored 
the effects of TLR3, 7 and 9 stimulation on MHV mouse infection. Thus, the animals were treated 
with Poly (I:C), Loxoribine and CpG, the respective TLR ligands. MHV-infected mice inoculated with 
Poly (I:C) had significant lower levels of plasma transaminases and Ig, anti-MHV Ab, and uric acid 
than MHV-infected animals, whereas autoAb to kidney tissue were observed. Loxoribine only 
produced a slight decrease of uric acid levels and serum Ig. CpG showed deleterious effects on 
MHV-infected mice, since survival of animals dramatically dropped to about 10%. AutoAb to mur-
ine tissues and uric acid release were not affected, whereas transaminases and anti-MHV Ab were 
slightly elevated. Besides, CpG administration produced a decrease of the high levels of serum Ig 
induced by the virus. Therefore, results indicated that TLR3 stimulation appeared to protect the 
animals against the viral infection, whereas CpG aggravated its signs. Loxoribine, the TLR7 ligand, 
did not show major effects. 
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MHV-A59 is an enveloped, positive-strand RNA Coronavirus that triggers various mouse pathologies, including 
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hepatitis, thymus involution [1], IgG2a-restricted hypergammaglobulinaemia [2] and transient demyelination [3]. 
We have reported the presence of autoantibodies (autoAb) to liver and kidney fumarylacetoacetate hydrolase 
(FAH) in sera from various mouse strains after MHV infection [4]. The autoAb recognized conformational as 
well as linear antigenic determinants in the enzyme, and the autoimmune response was partly related to molecu-
lar mimicry [5]-[7]. Furthermore, we have shown that the induction of the anti-FAH autoAb was associated with 
the MHV-induced release of some danger signals, or alarmins [8], such as uric acid and high-mobility group box 
protein 1 (HMGB1) [9]. 
To amplify the MHV actions we treated BALB/c mice with carbon tetrachloride (CCl4) after MHV infection. 
The association of MHV infection with the toxic effects of CCl4 resulted in hypergammaglobulinemia and the 
production of autoAb to various liver and kidney proteins, producing some signs that characterize the autoim-
mune hepatitis (AIH) [10]. Afterward it was observed that mice from the C57BL/6 strain were more susceptible 
to MHV-infection than BALB/c and thus developed several signs of AIH, i.e., hypergammaglobulinaemia, au-
toAb to liver antigens (Ag), elevated transaminases and, interestingly, liver infiltrates. In addition, the simulta-
neous treatment with the adjuvant PADRE [11] augmented some signs of the AIH-like disease [12]. 
Toll-like receptors (TLRs) play a central role in innate immunity as they detect conserved pathogen-asso- 
ciated molecular patterns (PAMPs) on a range of microbes, including viruses, leading to innate immune activa-
tion and orchestration of the adaptive immune response [13]. To date, a large number of viruses have been 
shown to trigger innate immunity via TLR, mainly TLR3, TLR7, TLR8 and TLR9, suggesting that these recep-
tors are likely to be important in the outcome of viral infection [13]-[16].  
TLR3 was originally identified as recognizing a synthetic analogue of double-stranded RNA (dsRNA), poly-
inosinic-polycytidylic acid (Poly (I:C)), which could mimic viral infection and induces antiviral immune re-
sponses by promoting the production of both type I interferon and inflammatory cytokines [13]-[16].  
TLR7, originally identified as recognizing imidazoquinoline derivatives such as imiquimod and resiquimod as 
well as guanine analogues such as Loxoribine, identifies ssRNA derived from RNA viruses such as vesicular 
stomatitis virus, influenza A virus and human immunodeficiency virus. TLR7 is highly expressed in plasmacy-
toid dendritic cells (pDC) that are able to produce large amounts of type I interferon after virus infection 
[13]-[16].  
TLR9 recognizes unmethylated 2’-deoxyribo(cytidine-phosphate-guanosine) (CpG) DNA motifs which are 
common in bacteria and viruses but rare in mammalian cells. Synthetic CpG oligodeoxynucleotides function as 
TLR9 ligands and directly activate DC, macrophages and B cells, and drive strong TH1 responses [13]-[16].  
Thus, to explore the relationship of TLR 3, 7 and 9 with MHV effects, we treated MHV-infected mice with 
Poly (I:C), Loxoribine and CpG, the respective TLR ligands. The results indicated that stimulation of TLR3 
slightly protected the animals against the viral effects whereas CpG administration aggravated the infection 
signs. Loxoribine, the TLR7 ligand, did not produce major effects.  
2. Materials and Methods  
2.1. Mice  
Specific-pathogen-free (SPF) female C57BL/6 (B6) mice from the University of La Plata, Argentina, were used 
at the age of 8 - 10 weeks. All animals were maintained in isolators, on standard laboratory chow, under SPF 
conditions until the end of the experiments, and received care in compliance with international legal require-
ments. 
2.2. Preparation of MHV Stock  
The NCTC 1469 adherent cell line derived from normal mouse liver was purchased from the American Type 
Culture Collection. Cells growing in T-75 bottles were inoculated with MHV A59 virus at a multiplicity of 1 - 5 
50% tissue infectious doses (TCID50) per cell. After an adsorption period of 1 h at 37˚C, 15 ml of NCTC 135 
medium with 10% fetal calf serum was added to each bottle and incubated at 37˚C. Several cycles of freezing 
and thawing were used to release the virus 24 h after inoculation. The harvested virus was centrifuged at 400 g 
for 10 min to remove debris and the supernatant was frozen at −70˚C for storage. Virus titration by endpoint 
method was performed by inoculating serial dilutions of the MHV stock onto cell monolayers in 96-multiwell 
plates. After 24 h, wells with viral cytopathic effect were counted for each dilution and titer was expressed as 
TCID50 [17]. 
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2.3. Viral Infection and Toll-Like Receptor Ligand Inoculation  
On day zero C57BL/6 mice were infected intraperitoneally with 104 TCID50 of MHV-A59. As described in 
Gustot et al. and Hayashia et al. [18] [19], on days −3, −1, 1, 3 and 5 pre and post-infection, mice were inocu-
lated intraperitoneally with 250 µl of saline containing 180 μg of Poly (I:C) (Sigma-Aldrich, St. Louis, Mis-
souri), 150 μg of 7-allyl-7,8 dihydro-8-oxoguanosine (Loxoribine, Sigma-Aldrich, St. Louis, Missouri) or 20 μg 
of CpG (ODN 1826, Integrated DNA Technologies, San Jose, CA). As a control, another group of mice was in-
fected only with the virus (“MHV” mice). Mice were bled by retro-orbital bleeding at 7, 20 and 50 days after 
infection. The animals were euthanized by cervical dislocation. 
2.4. Determination of Anti-MHV Ab by ELISA 
To test anti-MHV Ab, ELISA plates were coated with 100 µl of UV-inactivated MHV-A59, 2 × 107 PFU/well, 
diluted in 0.02 M glycine, 0.03 M NaCl, pH 9.2. After overnight incubation at room temperature and washing 
with phosphate buffer saline containing 0.125 ml of Tween 20 per liter (PBS-Tween), the plates were blocked 2 
h at 37˚C with 0.01 M Tris, 0.13 M NaCl, pH 7.4, containing 5% of fetal calf serum (TMS-FCS), which mini-
mizes non-specific binding. The plates were then incubated 2 h at 37˚C with mouse serum diluted in TMS-FCS 
and after washing with PBS-Tween, the bound Ab were revealed with peroxidase-labeled goat anti-mouse IgG 
(Ig-PO, Santa Cruz Biotechnology, CA, USA) diluted 1:10,000 in TMS-FCS. As a substrate, orthophenylene- 
diamine-dihydrochloride (OPD, Sigma Chemical Co, St. Louis, MO) with freshly added H2O2 was used. The 
reaction was stopped after 10 min by addition of 1 M H2SO4. The absorption was measured by ELISA reader 
(Metertech Inc., Taipei, Taiwan) at 490 nm. Non-specific values of optical density were obtained in the absence 
of mouse serum.  
2.5. Immunoglobulin (Ig) Assays 
For total Ig determination in mouse serum, microplates (Nunc Maxi-Sorb) were coated with 100 μl of phosphate 
buffer saline (PBS) containing a 1:500 diluted rabbit antiserum directed against mouse Ig. The plates were 
blocked for 1 h at 37˚C with 0.01 M Tris, 0.13 M NaCl, pH 7.4 (TMS) containing 5% of non-fat milk (TMS-M) 
and were incubated with serial dilutions of mouse serum in the same medium. After 2 h at 37˚C and washing 
with PBS containing 0.125 ml of Tween 20 per liter (PBS-Tween), the plates were incubated for 1 h at 37˚C 
with peroxidase-labeled goat directed against mouse IgG (Santa Cruz Biotechnology, CA, USA) diluted 
1:10,000 in TMS-M. The reaction was revealed as described in the above paragraph. 
2.6. Preparation of Liver and Kidney Extracts 
Livers and kidneys from non-infected C57BL/6 mice were removed, soaked in chilled PBS and ground in an 
Omni Mixer Homogenizer (Omni International Inc, USA) at 4˚C with 20 volumes of PBS containing 1 mM 
phenylmethyl-sulfonyl fluoride (PMSF) and 1 U∙ml−1 of trypsin inhibitor. The homogenates were centrifuged 
for 10 min at 400 g and the clarified extracts kept at −20˚C until used. A sample of each suspension was solubi-
lized by heating for 30 min at 100˚C in 1 M NaOH and protein concentration was determined according to 
Bradford method [20]. 
2.7. Western Blot Analysis 
Liver or kidney extracts (100 μg of protein) were submitted to 10% SDS-PAGE and then transferred onto nitro-
cellulose sheets (Amersham, Buckinghamshire, UK). After reversible staining with Ponceau S to check satis-
factory transfer, non-specific Ab-binding sites were blocked by incubating the sheets with 5% nonfat milk in 30 
mM Tris, 0.14 M NaCl, 0.1% (v/v) Tween 20, pH 8.0 (TBS-M-T) for 1 h at room temperature with shaking. The 
strips were then incubated overnight at 4˚C with an Ab dilution in TBS-M-T. After several washings with TBS 
containing 0.1% (v/v)Tween 20, bound Ab were revealed with peroxidase-labeled goat anti-mouse IgG (Ig-PO, 
Santa Cruz Biotechnology, CA, USA) diluted 1:10,000 in TBS-M-T and ECL Prime reagents (Amersham, 
Buckinghamshire, UK). In each experiment a negative control (pool of sera from non-treated B6 mice) and a 
positive control (pool of sera from MHV-infected B6 mice) were included. The apparent molecular mass (kDa) 
of the detected bands was determined using a wide range protein standard (BDH Laboratory Supplies Poole 
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BH15 1TD, UK). 
2.8. Transaminase Determination 
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined using the GOT 
(AST) and GPT (ALT) Unitest (Wiener Lab., Rosario, Argentina).  
2.9. Determination of Uric Acid Concentration in Plasma 
It was determined enzymatically using the assay kit Uricostat (Wiener Lab, Rosario, Argentina) using 1:50 di-
luted mouse sera as indicated by the manufacturer. 
2.10. Statistical Analysis  
Statistical significance between experimental values was calculated using the Student’s t-test or Mann-Whitney 
U-test. The Kaplan-Meier method was used to compare the differences in mouse mortality rates between groups. 
All statistical analysis were performed using GraphPad Prism (GraphPad Software, San Diego, CA). 
3. Results 
3.1. Serum Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)  
Values in Mice Submitted to the Various Treatments  
ALT occurs in large concentrations in the heart and liver with moderate amounts in skeletal muscle, kidneys, 
and pancreas, whereas AST is found in significant quantities in liver, kidney, and skeletal muscle, in decreasing 
order. As described before [12], we herein found that “MHV” mice exhibited elevated serum levels of ALT after 
7 days of treatment (Figure 1). Loxoribine or CpG treatment of infected animals did not change those facts, but 
there was a significant decrease of enzyme values under Poly (I:C) administration (Figure 1). After 20 days of 
treatment the enzyme levels decreased and no effect of the virus or TLR ligands could be observed. In the ab-
sence of infection, no effects of TLR ligands alone were found. Analogous results were obtained for AST de-
termination (data not shown). 
3.2. Total Immunoglobulin (Ig)  
Since MHV induces a non-specific B-cell activation [2] [12], present results indicated that “MHV” mice showed 
higher Ig levels than controls 20 days after infection (Figure 2). This hypergammaglobulinemia sharply decreased 
 
 
Figure 1. Levels of serum transaminases in mice submitted to the indicated treatments. ALT levels were de-
termined in pools of sera from five animals 7 days after each treatment and/or infection. The ligands used were: 
Poly (I:C) (TLR 3), Loxo (Loxoribine, TLR 7) and CpG (TLR 9). MHV: animals only infected. Control: ani-
mals without any treatment or infection. Levels of ALT in mice treated only with ligand were identical to con-
trols (data not shown). Statistical significance was calculated using the Mann–Whitney U-test. *P < 0.05.        




Figure 2. Concentration of total Ig in sera from mice submitted to the indicated treatments. Results 
were obtained with pooled sera from five mice at 20 days post infection and/or treatment. Values 
are expressed as the means of serum dilution to reach an OD of 1.0 at 490 nm. The tests were done 
in triplicate and were repeated at least three times with similar results. Statistical significance of 
values was determined by Student’s t-test in relation with MHV: ***P ≤ 0.001.                    
 
after treatment of the infected animals with either Poly (I:C), Loxoribine or CpG (Figure 2). Ligands alone did 
not affect Ig levels compared with controls (Figure 2). 
3.3. Anti-MHV Ab  
As described before [6] [12], anti-MHV Ab are observed some time after the inoculation of the virus (Table 1). 
Results indicated that treatment with Poly (I:C) slightly decreased the levels of anti-MHV Ab at 20 days after 
infection whereas, on the contrary, administration of CpG augmented these values and Loxoribine did not pro-
duce any effect (Table 1). Besides, in the absence of infection, a single administration of each ligand did not 
induce Ab to the virus (Table 1). 
3.4. Auto Ab to Liver and Kidney Tissues  
Western blot results confirmed that B6 mice infected with MHV developed autoAb to liver and kidney FAH but 
also to various non-identified proteins (Figure 3(a) and Figure 3(b)) [12]. Molecular mass of auto-antigens 
recognized by pooled sera after 20 and 50 days of treatment and/or infection indicated that the most reactive li-
gand was Poly (I:C). Thus, this ligand induced many autoAb to kidney proteins in MHV-infected animals, 
compared with the sole MHV effect (Figure 3(c) and Figure 3(d)). The amount of auto-antigens detected by 
sera from MHV-infected mice treated with Loxoribine or CpG was not different from that displayed by serum 
from “MHV” animals (Figure 3(c) and Figure 3(d)). Results also showed that TLR ligands, in absence of in-
fection, induced the production of some autoAb to liver and kidney extracts (Figure 3(c) and Figure 3(d)). 
As display in Figure 3(c) and Figure 3(d), Ab to liver and kidney FAH were present in pooled sera from 
MHV-infected mice, treated or not with the three different ligands. To confirm those results, the putative reac-
tivity of Ab to purified FAH, prepared as indicated in [4], was tested by Western blot. The results confirmed the 
absence of effect of any TLR-ligand on anti-FAH autoAb induced by MHV (data not shown). 
3.5. Uric Acid Release 
MHV-infection induces the liberation of uric acid into plasma [9] [12]. Under our experimental conditions, only 
Poly (I:C) and Loxoribine administration to MHV-infected animals slightly decreased uric acid release after 20 
days of treatment, whereas CpG did not produce any effect (Table 2). The administration of the ligands alone 
did not affect uric acid concentration compared with control values (Table 2). 




Figure 3. AutoAb to liver and kidney tissues in sera from C57BL/6 mice submitted to the indicated treatments. Upper part: 
Example of results obtained with mouse sera after 50 days of infection and/or treatment. Liver (a) and kidney (b) lysates 
were prepared as indicated in Materials and methods and separated by SDS-PAGE in 10% gels, transferred onto nitrocellu- 
lose sheets and incubated with 1:100 serum dilutions from pooled sera from five animals submitted to the indicated 
treatments. Bound Ab were revealed by peroxidase-labeled IgG anti-mouse IgG and ECL Plus reagents. P: Poly (I:C); L: 
Loxoribine; C: CpG; M: MHV; N: Control. Lower part: Summary of whole results obtained after three independent experi- 
ments. Western-blots were carried out as described above. Points indicated the molecular weights of proteins recognized by 
mouse sera after 20 (●) or 50 (○) days post-infection and/or treatment. FAH position is shown by dashed lines. c and d: liver 
and kidney tissue, respectively.                                                                             
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Table 1. Anti-MHV Ab in mice submitted to the different treatments and/or infection. ELISA 
microplates were coated with UV-inactivated MHVA59 (2 × 107 PFU/well) and incubated 
with pooled sera (diluted from 1:50 to 1:100,000) from five mice at 20 days post-treatment 
and/or infection. Results are expressed as the mean of three independent determinations to ob-
tain an OD of 0.5 at 490 nm and statistical significance was calculated with the Student t-test 
in comparison with “MHV” animals. *P < 0.05.                                         
Treatment Ab titer (1/dilution) 
Control 3800 ± 900 
MHV 29000 ± 6000 
Poly (I:C) 3500 ± 300 
Poly (I:C) + MHV 18000 ± 1700* 
Loxoribine. 8500 ± 200 
Loxoribine. + MHV 37000 ± 7000 
CpG 3500 ± 150 
CpG + MHV 42000 ± 4500* 
 
Table 2. Concentration of serum uric acid in mice submitted to the indicated treatments and/or 
infection Uric acid was assayed in triplicate on pooled sera from five mice, and statistical sig-
nificance was calculated with the Student t-test in comparison with “MHV” animals. *P < 0.05; 
**P < 0.005. Control (non infected animals): 16.1 ± 1.1 and 17.1 ± 1.2 mg∙ml−1 for 7 and 20 
days, respectively.                                                                
Uric acid (mg∙ml−1) 
Time after infection 
Treatment 7 days 20 days 
MHV 14.7 ± 0.6 19.1 ± 0.2 
Poly (I:C) + MHV 13.4 ± 0.2 17.2 ± 0.4** 
Loxoribine + MHV 13.4 ± 0.4 16.7 ± 1.5* 
CpG + MHV 14.3 ± 0.9 17.5 ± 2.0 
3.6. Effect of TLR-Ligands on Mouse Survival 
MHV-infection affected B6 mouse survival, since after 8 days of infection, about 60 % of mice were still alive, 
whereas 70% of animals inoculated with Poly (I:C) survived the viral infection (Figure 4). Besides, whereas 
Loxoribine did not affect mouse survival, CpG aggravated the MHV harmful action, as only 11 % of mice 
stayed alive at the end of the study. The Kaplan-Meier test was utilized to evaluate the differences in mortality 
rates between “MHV” mice and those inoculated with CpG (P < 0.05) (Figure 4). 
4. Discussion  
Up to now, a large number of viruses have been shown to trigger innate immunity via TLR, suggesting that 
these receptors should be important in the outcome of viral infection. Thus, many viruses have evolved mecha-
nisms not only to evade the innate immune system, but also to subvert it for their own benefit [13]. It has been 
described that the stimulation of TLR with their specific ligands promotes the secretion of pro-inflammatory 
cytokines and type 1 interferons (IFNs) [13]. Furthermore, it was demonstrated that signaling via the TLR di-
rectly or indirectly regulates the immunosuppressive function of Treg cells CD4+-CD25+ in graft rejection, au-
toimmune or infectious diseases, and cancer [21].  
To study the role of TLR 3, 7 and 9 on our model of MHV-infection and autoimmune response [9] [12], 
C57BL/6 mice were infected with MHV and treated with Poly (I:C), the ligand for the TLR3, Loxoribine to  




Figure 4. Effect of TLR ligands administration on survival of MHV-infected 
mice. Data are taken from three independent experiments, using 9 - 14 ani-
mals for any treatment. Symbols are as follows: MHV (●); Poly (I:C) + MHV 
(□); Loxoribine + MHV (∆) and CpG + MHV (▼). In controls (animals 
without any treatment) and in mice inoculated only with the TLR ligands the 
survival was 100% (data not shown). Survival was monitored daily for up to 
five weeks. The Kaplan-Meier test was utilized to compare the differences in 
mortality rates between groups (*P < 0.05).                               
 
stimulate TLR7 or CpG (ODN 1826), the ligand of TLR9. To examine the effects of the three TLR ligands we 
measured the levels of plasma transaminases, anti-MHV Ab, Ig concentration, autoAb to FAH as well as to liver 
and kidney tissues, uric acid liberation and mouse survival. The three ligands were also administered alone to 
non-infected animals. 
MHV-infected mice inoculated with Poly (I:C) had lower levels of plasma transaminases, serum Ig and uric 
acid than MHV-infected animals, but developed a remarkable amount of autoAb to kidney tissue, including auto 
Ab to FAH. However, Poly (I:C) did not affect mouse survival, indicating that autoAb did not produce any pa-
thological effect. Thus, the whole data suggest some protective role of TLR3 stimulation on MHV-infection. No 
effect was seen when only Poly (I:C) was administered. 
The putative defensive effect of Poly (I:C) described herein correlated with a similar “in vitro” activity of the 
TLR3-ligand on MHV-infected J774A.1 murine macrophages [22]. Thus, Mazaleuskaya et al. [22] found that 
pre-stimulation of TLR3 with Poly (I:C) hindered MHV infection through induction of IFN-β in macrophages, 
demonstrating that activation of TLR3 with the synthetic ligand mediated antiviral immunity that diminishes vi-
rus production [22]. It was also reported that Poly (I:C) could emulate viral infection and NK cell-mediated liver 
injury [23] but, under our experimental conditions, Poly (I:C) administration did not induce any pathological ef-
fect on mice despites the induction of some anti-kidney autoAb. These contradictory results could be explained 
by either the dose of ligand used and/or the shorter time of the observations, hours instead of days as in He et al. 
[23] experiments. 
Treatment of MHV-infected mice by Loxoribine, the ligand for TLR7, produced only a sharp decrease of se-
rum Ig and a slight decrease of uric acid levels. The lack of important Loxoribine effects was rather surprising, 
since TLR7 has been described as an innate signaling receptor that recognizes single-stranded viral RNA and is 
activated by viruses that cause persistent infections [24]. One possibility is that Loxoribine was not the satisfac-
tory ligand to stimulate TLR7 activity in our model of MHV infection, as shown by Rajagopal et al. [25] using 
different experimental procedures. 
The TLR9 ligand, CpG, showed deleterious effects on MHV-infected mice, since survival of animals dra-
matically dropped to 11%. AutoAb and uric acid release were not affected, whereas transaminases were elevated, 
even in spite of the lack of statistical significance because of the death of various mice. On the contrary, CpG 
significantly decreased serum Ig. In the same way, it has been reported that TLR9 stimulation promotes the ac-
cumulation and activation of hepatic CD4+ NKT cells by Kupffer cells and that pre-treatment with CpG aggra-
vates Concanavalin A-induced hepatitis [26].  
How to reconcile the fact that TLR9 recognizes DNA with the pathological effect of CpG on a RNA-virus in-
fection? One possibility is that proposed by Kaisho [27], CpG motifs are found in mammalian DNA, although 
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their frequency is much lower than in microorganism-derived DNA. Thus, since TLR9 is localized in the endo-
plasmic reticulum and can migrate into endosomes, where uninfected host-derived cells can be incorporated, 
TLR9 should have the potential ability to provoke immune responses against self nucleic acids [27]. Another 
option is to take into account the role of HMGB1, liberated by MHV-infection as shown previously [9] [12], in 
infection-induced inflammation. In fact, it was reported that HMGB1 could bind to LPS, CpG, viral RNA and 
IL-1, significantly increasing its inflammatory activity [28]. 
Main results presented here suggest that MHV effects are related to both TLR3 and TLR9. TLR3 activation 
by Poly (I:C), should protect the animals against the infection trough the liberation of Type I interferons whereas 
CpG would synergize the MHV activity thus enhancing the deleterious viral effects. Remarkably, the three li-
gands, producing different effects on animal survival and other parameters shown herein, decreased serum Ig, 
indicating an inhibition of the polyclonal activation produced by the virus. To our knowledge, this effect was not 
described in the literature, but may be related to the fact that TLR are also present in B-cells [16]. 
TLR agonists are being tested in vaccines against hepatitis C and influenza as well as in allergic rhinitis and 
certain cancers [14]. TLR 3, 4, 7, 8 and 9 are all validated targets for cancer and a number of companies are de-
veloping agonists and vaccine adjuvants [29]. Thus, although the prospect of targeting TLRs in multiple pathol-
ogies continues to hold much promise, our observations suggest that CpG should be kept away from treating 
people under viral infections, mainly hepatotropic agents.  
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